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Medical Hegemony and 




Better human healthcare is achieved by increasing the fair use and accessibility 
of medical information. While this optimism is believed, real-world healthcare can 
be severely affected by the knowledge and context shared in the healthcare industry 
and academia. Through the sharing process, the central perception gains consensus 
in the industry and academic societies and standardized therapies are unified and 
spread quickly. In this way, mainstreamers’ contexts quickly become standard-
ized. Consequently, the mainstream has hegemony and can be strengthened. 
Mainstreamers neglect any information different from standardized knowledge and 
therapy. It is universally known that hegemony stabilize its position by undermin-
ing the fair use and accessibility of information. The use of patterned knowledge 
facilitates the utility of medical information. Smart ICT seems to realize the smart 
use of medical information in our daily lives as well as professional exercises. The 
method to eliminate such evils and realize true health care is required. The fair 
use and accessibility contribute to the utility of medical knowledge to end-users. 
The effect and influence of the commons of information are shown as a solution to 
eliminating adverse events caused by the hegemonic mainstream. As the most effec-
tive means in the coming digital healthcare era, this paper shows the following three 
points. (1) Allow commons of information to enable fair use and search of informa-
tion. (2) The commons of information release the cognitive bias set by the measure. 
(3) By creating such a new theory, we will develop a new field called healthcare 
digital management and/or healthcare digital economics.
Keywords: healthcare, hegemony, centrality, commons of information, network, 
neutrality
1. Introduction
Achieving wellness and hence well-being is the goal of every human being. On 
the global scale this is articulated through the Millennium Development Goal and 
SDGs (Sustainable Development Goals) of the United Nations.
The science of medical and health care has transformed the health care profes-
sion by the extraordinary revolution in information technology. To utilize the true 
results of science, the use and accessibility of information among different health-
care professionals through network neutrality realize the true human healthcare, 
bringing the world together as a true global village.
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2. Accessibility to medical and health care as public goods
It is believed that the better access by ICT will improve information barrier-free, 
grassroots information dissemination, and information sharing. Better human health 
care will be achieved by increasing the accessibility of healthcare information. While 
this optimism is believed, real-world healthcare has been severely affected by the 
shared information among the healthcare industries, professionals, and academia.
If information is not transmitted correctly without distorting the truth, life-
threatening situations occur frequently. However, healthcare is usually neglected 
because it is only demanded when a person becomes unhealthy. Therefore, the 
supplier can behave to get the best benefit from diseases. What’s worse is that the 
higher the need, the more urgent it is.
Due to the above circumstances, the health care provider is likely to take self-
interest behavior. To curb such behavior, better access to information does not solve 
the problem. This is because the information is cleverly rewritten to suit the interest 
of mainstream in the healthcare industry without being noticed. In this chapter, I’ll 
take a few such mysterious cases and explain why.
2.1 Inclusion of total healthcare by the mainstream in healthcare
According to the Merriam-Webster Dictionary, healthcare is efforts made to 
maintain or restore physical, mental, or emotional well-being especially by trained 
and licensed professionals. There are mainstreams and adjuncts among profession-
als. The mainstream is the most influential actor and is in a privileged position. To 
maintain privilege, it is common for mainstream people to try to establish a hege-
monic position by involving their adjuncts.
In healthcare, medical care is at the center and all other healthcare areas are 
adjuncts. In medical care, treatment is at the center of the center, and prevention 
is one of adjuncts. Considering the pursuit of profits and strengthening of the 
position of medical care providers, it is better to increase the number of patients 
without prevention even if some patients must die. As a supporting evidence, in the 
pharmaceutical industry, it is an implicit understanding that the companies should 
not develop drugs that eliminate diseases, because the market will disappear like 
smallpox market by its vaccine. That is why RNA vaccine, which works faster and 
more effective than ordinary protein vaccines, did not take place until it was urgently 
approved as a corona vaccine. If RNA is used to produce stem cells, iPS cells (induced 
pluripotent stem cells), pluripotent stem cells, regenerative medicine for diseases 
including aging care and immunotherapy for the treatment of cancer will advance 
dramatically. Complete treatment of disease, organ regeneration, and immortal 
medicine have been hampered by mainstream groups to professionals. Mainstream 
has denied such a wonderful future as disease-free and immortal medical care.
The medical professionals should be humble about the dignity of life. When new 
facts are discovered, it is up to the mainstream to spread or not. The mainstream 
instantly includes new discoveries that can deny the mainstream. However, the main-
stream attacks and denies the new discovery which can coexist with the mainstream. 
The reasons and causes for such absurd things to happen are for the benefit of the 
mainstream. Various inhumane obstacles occur, so the details are described below,
2.2 The difference in accessibility to medical care between Japan and the US
The openness of medical care is the exact opposite in Japan and the US. In Japan, 
not only paramedics but the nurses only can watch the patients die until the doctor 
arrives. Oppositely, in the US, medical practice is open to medical assistants and 
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paramedics. They can take life-saving measures for emergency patients who are 
clearly likely to die if left untreated.
Why does such a difference between the two countries occur? In short, it 
depends on whether the market is free or regulated. The American way seeks 
efficiency through a free and open market. The Japanese government operates 
policies assuming that medical care is at the center and others are adjuncts. This 
is derived from the fundamental differences in public policies between the two 
countries.
The U.S. government and its local agency, the U.S. embassy, have repeatedly 
demanded the Japanese government to open and liberalize the medical and health 
care market, but with no success, while promoting the reasons for the free-open 
market. For American businesses to enter the Japanese market, it is essential to 
deregulate the Japanese market. The U.S., which had been the world’s factory until 
Japan emerged, has attempted to take an initiative to the world’s industry by securi-
ties financing. Therefore, the US government must protect the domestic market 
from foreign countries but ask free and open markets to foreign governments for 
maintaining a global hegemony. Such American diplomacy is well-known as a 
double standard. The importance of the role of government is strongly asserted by 
American economists. It is the American way to manage social welfare services such 
as medical care based on the principle of competition that works in an open market. 
Consequently, the gap about accessibility to medical care between Japan and the U. 
S. has been still expanding. Table 1 shows the accessibilities to medical care by costs 
for treating appendectomy in major countries.
According to the Japan Medical Association, the US is the country with the 
widest medical disparity in the world. “Public medical insurance in the US is limited 
to “Medicare” for the elderly aged 65 and over and persons with disabilities, and 
“Medicaid” for low-income earners. The active generation, which is not covered by 
these two, is mainly covered by private medical insurance. The so-called “Obama 
Care” obliges people who do not have public medical insurance to join a private 
insurance company, but there are only a limited number of medical institutions 
available for medical examination. Many people are still uninsured in order not to 
be able to pay the insurance premium. There is a big disparity in the medical care 
provided” [1].
Rank City Expenses (US$) Hospitalization Days
1 New York (US) 14,000-40,000$ 1–3 days
2 Paris (France) 2,000-8,800 days
3 Madrid (Spain) 4,000-8,350 4 days
4 London (UK) 6,700 2 days
5 Rome (Italy) 6,300-6,650 3 days
6 Geneva (Switzerland) 2,530 3 days
7 Vancouver (Canada) 6,060 3 days
8 Singapore (Singapore) 3,180-3,970 3 days
9 Dusseldorf (Germany) 3,250 3 days
10 (General example) (Japan) 2,730 6–7 days
Cited from Tokio Marine & Nichido Fire Insurance Co., Ltd.
Source: Japan Medical Association Homepage: “World Medical Care and Safety 2010” [1].
Table 1. 
Costs for treating appendectomy in major countries (accessibilities to medical care by costs).
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In Japan, medicine and healthcare are recognized as public goods. The govern-
ment has, therefore, an obligation to protect the domestic market from free-com-
petitive destruction. Japan attaches great importance to accessibility that anyone 
can access anywhere and fair use of medical care as public goods. The Government 
of Japan is responsible for ensuring that all the people can receive the necessary 
medical care. Therefore, a fundamental difference between the two countries exists 
in the medical care and healthcare.
Until around 1955, about 30 million people, mainly farmers, self-employed, 
and employees of micro enterprises, which is about one-third of the population, 
were uninsured in Japan, which was a social problem. However, the National Health 
Insurance Law was enacted in 1958, and the National Health Insurance business 
began in municipalities nationwide in 1961, establishing a system that allows 
“anyone,” “anywhere,” and “anytime” to receive insurance medical care [2].
Japanese Ministry of Health, Labor and Welfare has declared that the role of this 
system as a safety net is essential as follows:
“Under the universal health insurance system, Japan has realized a medical system 
that allows anyone to receive medical care securely and has achieved the world’s highest 
average life expectancy and health care standards. We will continue to aim for a sustain-
able public medical insurance system in response to the declining birthrate, increase in 
the aging population, population, and changes in the economic situation” [3].
2.3 The centralization power by mainstream in the US
From the social side, mainstream blocks the entry of others to strengthen its 
power. Mainstreamers can get various benefits and others are excluded. Partial 
optimization for mainstream results in the lack of total optimization as shown in 
Table 1. On the economic side, mainstreams amplify their interests while blocking 
the entry. This accelerates the centralization by mainstream, that starts to have 
a gravitational force that attracts various things. Mainstreamers begin to exert 
hegemonic influence to stakeholders and concessions authorized by the government 
create a chain of interests.
From the standpoint of the government and the market, initially, everything 
starts with a good idea for society, but policies act to fix benefits. They compete for 
the pie of government budgets. Governmental policies will be taken to ensure vested 
interests. Historically, the economy has set the direction for government. In the US, 
the globalized economy has gained centrality, set the direction of government, and 
could therefore gain the hegemony in the healthcare. Thus, as a result, a mechanism 
has been created in which mainstreamers increase profit and the public does not get 
the lowest benefits in the world.
2.4 The power of centrality to the publicity in the US
On the publicity in the US, at the center of political economy, the centrality deter-
mines everything through funding for politicians, the media, university professors, 
and researchers. It is well known that every public good is commercialized in the US 
by the logic, that competition in the market is better than government control.
The situation surrounding the potentially life-threatening medical care is dire 
and irreversible. A typical example is Medicaid. Medicaid is a government medi-
cal benefit system for low-income people who have difficulty in taking out private 
medical insurances (including persons with disabilities and pregnant women who 
are recipients of supplementary income security). The cost of Medicaid is increas-
ing from 1980s’ when market fundamentalism was applied to medical care, as 
shown in Figure 1.
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Regarding medical expenses in the US, according to the Medicare Medicaid 
Service Center in the US, medical expenses in the US in 2018 totaled $ 3.6 trillion, 
and $ 11,172 per capita. It accounts for 17.7% of GDP. The medical cost per capita in 
Japan is $ 2,920 (321,100 yen), which is almost four times higher.
Even though medical expenses and the US government spending on per capita 
are the highest in the world, it is far from a universal service that allows people to 
live safely, securely. Only the US and Mexico have failed to achieve universal health 
care in OECD countries [4]. The lack of medical insurance in the US causes 45,000 
to 48,000 unnecessary deaths each year [5, 6]. About 25 percent of young citizens 
have filed for bankruptcy due to high medical costs, and 43 percent of them have 
sold real estate for that purpose [7].
In the US, the power of centrality introduces market principles to what is in 
publicity, and businesses succeed in profiting from the people and the government, 
resulting in poverty and pressure on the government’s finances.
3. Accessibility and medical hegemony
3.1 Accessibility to healthcare
As mentioned above, there is a negative correlation between the degree of 
inequality and accessibility. What makes the difference between Japan and the US? 
Japan focuses on protecting people. Japan is a country that values dignity for life 
and ethics. In the US as well, business executives were highly aware of high moral 
aspirations, wide moral foundation [8] and public institutions [9] for people and 
society till 1950s’.
Due to the championship of huge securities financing capital, globalization 
has been progressing in the US. As the securities financing business has played a 
central role in the US economy, the US have assumed that free competition in  
the market would solve social problems. Free competition strategy has helped the 
US securities financing industry rule its economic and political hegemony in the 
global market.
The US spends the most on health care in high-income countries. Total medical 
expenses per capita has been continuously rising from 1981 [10]. Table 2 shows 
the ranking of medical expenses per capita. The total medical expense per capita 
in the US is 2.22 times that of Japan, 2.60 times that of the United Kingdom, and 
Figure 1. 
Public healthcare insurances and social security expenses in the United States (Wikipedia) [Internet]. 2021. 
Available from: https://commons.wikimedia.org/wiki/File:Medicare,_Medicaid,_and_social_security_
spending.png [accessed: 2021-6-7 including citations in the text below].
Healthcare Access
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2.65 times that of the OECD average. Total medical expense of the US is the highest, 
despite the worst medical care for the public.
In Japan, Japan’s Big Bang package was done from April 1, 1998 to March 2001. 
The first liberalization removes barriers for foreign companies to buy or to sell 
Japanese companies. As a result, shareholders started to ask high dividend on stock. 
Restructuring was carried out as companies prioritized immediate profits over the 
future. The unemployment rate in Japan is steadily increasing, and the number of 
non-regular employees is also increasing, which is a factor of disparity.
Regarding healthcare system, Japanese public opinion and the government have 
not chosen the policies to widen the inequality, because the right to life is guaran-
teed by the Constitution as well as the right to live a healthy and cultural life. On the 
contrary, there is no right-to-life clause in the US Constitution.
3.2 Affordability and timeliness determine the health of people
According to WHO (the World Health Organization), a well-functioning 
healthcare system requires a steady financing mechanism, a properly-trained 
and adequately-paid workforce, well-maintained facilities, and access to reliable 
information to base decisions on. These include the care process (preventative care 
measures, safe care, coordinated care, and engagement and patient preferences), 
Country Healthcare Rank Total medical expenses per capita (US$)
















Oceania Average 16 4,463.98
Iceland 17 4,349.09
Finland 18 4,235.55
United Kingdom 19 4,069.57
OECD Average 3,992.35
Source: OECD Health Data.
Table 2. 
Ranking of medical expenses per capita in 2018.
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access (affordability and timeliness), administrative efficiency, equity, and health-
care outcomes (population health, mortality amenable to healthcare, and disease-
specific health outcomes) [11]. Based on these five measures, WHO publishes 
health system rankings “Measuring Overall Health System Performance for 191 
Countries” as shown in Table 3.
Yet the U.S. population has poorer health than other countries. Life expectancy, 
after improving for several decades, worsened in recent years for some populations, 
aggravated by the opioid crisis. In addition, as the baby boom population ages, more 
people in the US—and all over the world—are living with age-related disabilities 
and chronic disease, placing pressure on health care systems to respond [12].
A study by The Commonwealth Fund [12] used these metrics to rank 11 coun-
tries based on their quality of healthcare. The top-ranked countries are the United 
Kingdom, Australia, and the Netherlands. Regarding care process, the US also 
performs above the 11-country average on preventive measures like mammography 
screening and older adult influenza immunization rates. However, the US performs 
poorly on several coordination measures, including information flows among pri-
mary care providers, specialist and social service providers. The US also lags other 
countries on avoidable hospital admissions.
Among them, the US ranks last on Access. The performance of the U.S. is the 
worst in all countries on the affordability subdomain, scoring. According to these 
discussions, there is no dispute that affordability and timeliness are key elements of 
accessibility. And these factors determine the health of the people in a nation.
3.3 Centralized power of mainstream and innovation
Because of the Japanese strict national licensing system, medical insurance 
companies lacked the willingness to take on new challenges. Take advantage of the 
opportunity not to change anything, cancer insurance had come from the US. The 
typical success case of the US was the monopoly of cancer insurance in the Japanese 
market by Aflac, a small US insurer, which prevented Japanese insurance companies 
not to enter the market from1972 to 2001. The US has repeatedly made demands for 
the US industries, as Japan has always been reluctant and weak against the demands 
of the US. Japan-US insurance talks held at the same time as the talks to break the 
trade conflict between Japan and the US. At that time, the original purpose was 
trade negotiations, but regardless of that, the US securities financing industries, 
which have economic and political central influence in the US, aimed to enter the 
Japanese market. It is agreed that cancer insurance and medical insurance cannot be 
sold by Japanese major life insurance companies and non-life insurance companies 
in Japan. As a result, Japanese insurance companies have been unable to enter the 
market for a long time, and Aflac, which entered the Japanese cancer insurance 
market in 1974, maintains an overwhelming market share.
By this time, the US had already shifted its focus from manufacturing to 
securities financing. During this period, policy had shifted to increase interna-
tional influence through the securities financing industries for overwhelming the 
industrialized nation of Japan. Economists had gotten influential power on federal 
policymaking since the late 1960s, leading the US in the wrong direction about 
domestic healthcare system and fostering social disparity. The big problem was that 
many economists unconditionally believed that free competition and free trade 
were best. Many economists sacrifice welfare and prioritize efficiency.
It is the American way to manage social welfare services such as medical care 
based on the principle of competition that works in an open market. This has made 
the healthcare industry inefficient, as afore mentioned in the former sections. The 
cost of treatment for common illnesses became unusually high after 1980. Disparity 
Healthcare Access
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Country Healthcare Rank 2021 Population
France 1 65,426,179
Italy 2 60,367,477























Saudi Arabia 26 35,340,683









Costa Rica 36 5,139,052
United States 37 332,915,073
Table 3. 
Ranking of well-functioning national healthcare systems in 2021 (by WHO) [10].
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expanded among professionals as well. Low quality doctors go to poor areas. 
Excellent doctors who can get a high salary gather in the area where rich people live. 
Medical disparities are further widening due to the phenomenon of cream skim-
ming, which businesses only enter profitable areas. Medical disparity is a detrimen-
tal effect of free competition. Therefore, there will be many medical refugees who 
cannot receive the necessary medical care like developing countries.
On the other hand, Japan attaches great importance to fairness in accessibility 
that anyone can access anywhere. To give the simplest example, in Japan, anyone 
can be treated equally by a well-known doctor in any hospital without appointment. 
As a code of ethics to guarantee the access, doctors are prohibited by law from 
refusing to see a patient.
It looks like the government is providing good health care, but it won’t do 
anything new. Therefore, organizations that should promote innovation can defend 
themselves. Such a thing was permitted within the authorities, so the approved 
ranking of anti-corona vaccines was the last among developed countries. In addi-
tion to the delay in approval of the vaccine against the anti-cervical cancer virus, 
which has confirmed clear efficacy and had been approved in advanced countries, 
it has not been approved for use by men. This is because the head of the vaccine 
department of the authorities continued to extend approval to the next person in 
charge for fear of side effects.
The John Maddox Prize is an award given by “Nature” to those who have contrib-
uted to the dissemination of science and scientific evidence for the public good. In 
2017, it was presented to Riko Muranaka, a medical doctor and journalist who has 
continued to send out information to verify the safety of the HPV vaccine. Nature 
described the HPV vaccine as “recognized by the scientific community and medical 
community as a key to preventing cervical cancer and other cancers and endorsed 
by the WHO (World Health Organization).” Moreover, in Japan the vaccine has 
been subject to a national misinformation campaign to discredit its benefits, results 
in vaccination rates falling from 70% to less than 1%. “ Nature evaluated her activi-
ties as “spreading science and scientific evidence for the public interest while facing 
difficulties and hostility,“ and selected from 100 candidates from 25 countries. Ms. 
Muranaka said, “I think it’s powerless to see that the situation has not changed even 
though I’ve written so much.“ The biggest problem is not being there. The nation 
must take responsibility for the lives of its people. “ Nature severely criticized the 
situation in Japan, saying that “a false information campaign that undermines the 
reliability of this vaccine was carried out nationwide” [13]. The data to disseminate 
false information was deliberately forged by an authoritative university professor 
who received research funding from the authorities to create fake data to deny.
For public interest, universal services should be obliged by the government to 
provide benefits to all, regardless of wealth, social class, men and women of all 
ages, or region. Even in Japan, where bioethics and publicity are the top priorities, 
the reality is beyond imagination. Professionals try to be central by acting for their 
own benefit. Once power is centralized, it is a virtue within the mainstream to not 
change unless it is related to their own interests.
3.4 Lack of accessibility due to medical hegemony
The US government and scholars argue that if regulators decide everything, 
they will not be able to provide adequate medical care to the public. This is because 
regulation would make it as if there was only one monopoly and would not try 
for customers [14]. Mainstream scholars such as Michael Porter have argued 
that better medical care should be provided in the competition. In fact, the most 
advanced medical care is being developed and provided in the US. As a result, the 
Healthcare Access
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most expensive medical ecosystem in the world and the lowest accessibility among 
developed countries has been created.
Figure 2 shows the annual change in the monopoly of American hospitals. An 
HHI (Herfindahl–Hirschman Index) score is the sum of the squares of the market 
share of each player in a market. For example, in a market where there is only one 
hospital — a monopoly — with 100 percent market share, that market’s HHI score 
is 10,000 (100 squared). A market with only two hospitals, in which one has 60 
percent share and the other 40 percent, has an HHI of 5,200 (60 squared plus 40 
squared). The Federal Trade Commission considers markets to be “highly concen-
trated” if their HHI scores are 2,500 or higher. In other industries, such as airlines 
or cell-phone carriers, the FTC routinely seeks to block mergers that would increase 
HHI scores above 2,500. In the hospital industry, however, the median market HHI 
exceeded 2,500 in the year 2000 and reached 2,800 in 2013 [15].
A new wave of hospital mergers is driving market concentration higher. The blue 
bars denote the number of merger and acquisition transactions in a given year; in the 
1990s, penetration of managed-care insurers, with a mandate for more aggressive 
cost control, led hospitals to merge in response, strengthening their market power 
over the insurers. The Federal Trade Commission (FTC) and the US. Department of 
Justice (DOJ) normally consider markets with an HHI above 1,500 as “moderately 
concentrated” and markets with HHI above 2,500 as “highly concentrated,” trig-
gering antitrust litigation. However, consolidated hospital markets have largely 
avoided antitrust litigation. In 21th century, more than half of the hospital markets 
in the US have an HHI above 2,500, meaning that the FTC and DOJ would consider 
them to be “highly concentrated” (Sources: A. Roy/FREOPP analysis and graphics, 
Robert Wood Johnson Foundation, Martin Gaynor, Irving Levin Associates, HHS 
ASPE.) [15].
Figure 2. 
Annual trends in the degree of monopoly by large hospitals in the US (source: “Avik Roy, The Foundation for 
Research on Equal Opportunity”).
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Market concentration contributes to raising the profit margin not only in the 
medical industry but also in the healthcare industry to get the highest interest rates 
in the world. In conclusion, the medical industry, which has increased its centrality 
by concentrating, is the most profitable in the world. The influence of this medical 
hegemony has resulted in poor accessibility to health care in general.
4. Opening medical barriers with digital healthcare
4.1 Barriers built by medical hegemony
The situation in which a hospital becomes huge and has an impact on overall 
health care could be defined as medical hegemony. According to WHO, universal 
healthcare can be determined by three critical dimensions: who is covered, what 
services are covered, and how much of the cost is covered [16]. In the US, hospi-
tals, health insurance companies, and pharmaceutical companies have become 
huge after 1980. Such huge healthcare providers have taken medical hegemonies 
and guide policies. Eventually, lack of accessibility results in unsatisfactory 
access to the medical needs of the public. As a result, WHO and the National 
Academy of Medicine and others have concluded the US is the only wealthy, 
industrialized nation that does not provide universal health care in 2021.
Medical care has its own peculiarities. In the medical and long-term care fields, 
only the provider has the information. Patients have no choice but to believe and 
entrust without bargaining even if they lie. Therefore, those who provide low-cost 
and high-priced medical care services accumulate profits and dominate the mar-
ket. Once become huge, they can affect various fields and the hegemony has been 
established.
Even if information is disclosed for the purpose of resolving information asym-
metry, it is practically impossible for consumers to have equal bargaining power. 
Therefore, in free competition, the supply side has an absolute advantage in decid-
ing what to do. In free competition in a state where information is asymmetric and 
bargaining power is imbalanced, prices rise by the following mechanism, resulting 
in the exclusion of consumers [17].
1. If the information is completely asymmetric, free competition will bring about 
market failure. Consumers do not know whether good or bad (lemon), so the 
bad suppliers survive and the good suppliers disappear. As a result, inferior 
products (lemon) are on the market. (The market for lemons)
2. If there are essential remedies and treatment methods, the supply side can raise 
the price as the demand increases. This is the result of price equilibrium when 
demand increases for limited resources (rents) such as land. (The law of rent)
3. The best management strategy for the supply side is to enter the market with 
the highest profit margin. Competitors lose if they do not do the same. (Pris-
oner’s dilemma causes bubbles and injustice).
4. The optimization strategy for the supply side causes inefficiency of the entire 
industry and create barriers that customers cannot get involved with. (Total 
inefficiency by partial optimization)
In the free competition market, there are many people who cannot receive 




Transition of hegemonic countries [18].
afford high treatment can enjoy exclusively top-level medicine. Thus, the barrier 
between supply and demand remains high. The gap in accessibility from consumers 
deepens and cannot easily repair once medical hegemony is fixed.
4.2 The source of hegemonic power
Digital healthcare is expected to increase the accessibility of medical informa-
tion and to remove the medical barrier. Although this optimism is believed, real-
world healthcare can be severely affected by the knowledge and context shared in 
the healthcare industry and academia. The problem is that common knowledge is 
spread by mainstream people.
The use of patterned knowledge from mainstream facilitates the use of medical 
information. Further utilization of smart ICT will facilitate to realize the smart use 
of medical information in our daily lives and therefore improve the accessibility to 
healthcare information. Through this process, the central perception will quickly 
gain consensus in the industry and academic societies. Through such a process, 
practical knowledge is unified and spreads quickly. In this way, mainstream con-
texts quickly become more and more widespread. In other words, this makes it 
easier for mainstream to establish hegemony.
Hegemons have become the center of the world and gained centrality by set-
ting a global standard. This strategy allowed hegemony to accumulate economic 
power and become the center of politics, economy, and society. To maintain 
centrality, hegemons have no choice but to do rent seeking for themselves, not 
for the total benefit. Figure 3 illustrates the transition of hegemonic nations. The 
hegemonic nation is deprived of the next hegemony by a neighboring country 
across the sea. By imitating and improving the previous economic system,  
neighboring countries that do not interact directly have become hegemonic 
nations one after another [18].
1. Egypt prospered from the fertile land of the Nile and its slave civilization. 2. the 
Greek police nations become the center of trade, 3.Rome is based on the vast terri-
tory that supplies slaves, 4. Islam relays East-west trade, and 5. Spain mined gold and 
silver in South America and circulated minted coins in Europe. 6. the Netherlands 
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became the global trade center with currency exchange, 7. the United Kingdom 
became the financial center (Citi) and the world’s factory by Industrial Revolution, 
8. the US became the world’s factory by the mass production system and then global 
securities and financial center, 9. Japan realized mixed production system with small-
volume plus mass customization and became the world’s factory, 10. South Korea, 11. 
Taiwan, and 13. China acquired the world market with imitation power.
A hegemon could become the center of the world by imitating and surpassing 
the previous hegemonic power [19].
The reason for the emergence of hegemonic states can be seen from the fact that 
the source of hegemony is not civilization but economic power.
4.3  Success/failure judgment method for information issued by medical 
hegemony
Can doctors adhere to justice fairly and selflessly in all situations? Hippocratic 
oath is an international norm that doctors should comply with. The ethical code 
attributed to the ancient Greek physician Hippocrates, adopted as a guide to 
conduct by the medical profession throughout the ages and still used in the gradu-
ation ceremonies of many medical schools. The oath dictates the obligations of the 
physician to students of medicine and the duties of pupil to teacher. In the oath, the 
physician pledges to prescribe only beneficial treatments, according to his abili-
ties and judgment; to refrain from causing harm or hurt; and to live an exemplary 
personal and professional life (Encyclopedia Britannica).
In the medical world, the problem is physicians have never accepted novel 
approaches when treatments does not replace current therapy. Players in the 
mainstream (stakeholders such as opinion leaders, physicians, pharmaceutical 
firms, university professors etc.) are not only reluctant to try any noble therapeutic 
approaches, but they have always denied and attacked.
It is well-known that medical hegemony intends to stabilize its position by 
undermining the fair use of information. For judging the correctness of medical 
information, it is possible to check simply whether one piece of simplified informa-
tion is yes or no. Yes/no methods can clarify responsibility in the event of an error. 
RNA injection is a typical example that used to be no but became yes. The proper-
ties of cells can be altered by introducing RNA instead of genetic engineering. 
Therefore, the rapid supply of corona RNA vaccine became possible. In addition, 
RNA injection can be used for in vivo production of pluripotent cells instead of in 
vitro production of iPS cells.
RNA injection method was denied by mainstreamers. This is explained by 
inevitable win-lose theory that indirect competitive innovation is neglected by 
mainstreamers. Surprisingly, in case of direct competition, mainstreamers accept 
new thing, but in case of indirect competition, they deny the new one [19–22]. The 
reason is that they will be replaced by challengers if they do not accept directly com-
petitive thing. However, without exception, they deny new things that indirectly 
compete with. Usually they spread fake information. They choose the immediate 
stability because they cannot be replaced immediately. It often takes time to be 
replaced, but the mainstream faction changes. It should be noted that both actions 
are taken to defend the position of the championship.
Nevertheless, professionals will continue to disseminate the information 
claimed by the mainstream. This is because expressing disagreement has adverse 
events. Whenever novel treatments are discovered that do not directly replace 
traditional one, they are denied without evidence and prevent them from being 
adopted. Table 4 shows categorized patterns of disinformation deliberately  
created by the mainstreamers [23].
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1. CV (Cardiovascular) was the most major therapeutic area in the world. Ca 
blocker has created a market with a particularly high share in Japan.  Authorities 
in the CV area were respected as representatives of physicians. This therapeutic 
area covers not only hypertension, but also all over the lifestyle-related disease. 
In this type of prioritized therapeutic area, companies create mainstream by 
writing treatises and giving research achievements to company-nominated 
opinion leaders, young doctors, and supporters based on each strategy. There-
fore, major physicians in the CV field have kept a tight relationship with 
pharmaceutical firms and have received financial support especially as research 
fund. Pharmaceutical companies have also set up programs to train prominent 
young doctors for next new product developments and marketing purposes.
According to major Japanese pharmaceutical firms, fast onset was the key point 
of Ca blockers. Therefore, common opinion was that there were few cases to be 
targeted by a new ARB (Angiotensin receptor blocker) therapy because ARB is not 
fast-acting. However, the fact was exactly the opposite. Only amlodipine, which had 
a slow onset and a long half-life just like ARB, was increasing sales.
In Japan, all opinion leaders and major journals did not support ARB, even 
after ARB became the first choice among all other countries. By author’s effort, 
a Japanese firm could get a license of ARB from a German big Ca player despite 
company-wide opposition.
Despite such industry-wide dissenting opinions, the share of the new therapy 
reached over 70% of the patients once the first ARB was launched. Although the 
overall evidence approved lifestyle-related diseases, professionals ignored the merit of 
organ-protective effect of ARB. Mainstream companionship is not evidence-based.
Therapy Traditional Novel therapeutics
1) Few targeted patients
CV in Japan (Cardiovascular) Ca blocker ARB (Angiotensin receptor blocker)
2) Slow onset of effect
GI in Japan (Gastrointestinal) H2 blocker PPI (Proton pump inhibitor)
Helicobacter pylori extermination
3) Not immediate effect
Anti-cancer drug Chemotherapy Antibody drug, cancer vaccine
4) High satisfaction
RA (Rheumatoid Arthritis) Symptomatic treatment (MTX: 
methotrexate)
Antibody drug (anti-TNF)
5) Evaluation criterions are unknow
Transfusion alternative Red blood cells transfusion EPO (Erythropoietin, red blood 
substitute)
6) Biopharmaceuticals Small compounds G-CSF
7) Regeneration No way iPS cells, RNA drugs
8) Oligonucleotide 
Therapeutics
Oligonucleotide does not enter 
the cell.
Anxiety of possible genetic 
mutations, without evidence
RNA or DNA injection,
Speed-up approval for in vivo 
antibody production against 
coronavirus
Autologous cell therapy by 
pluripotent cell proliferation
Table 4. 
Disinformation on novel therapy created by the mainstream [23].
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2. GI (Gastrointestinal) area is the largest market in the world till around 2010. 
A world-top share H2 (Histamine 2 receptor) blocker was originated by a 
Japanese firm. It was well recognized among Japanese firms and mainstream 
professors that extermination of H. pylori, the causative bacterium, would 
completely cure the gastric ulcer and prevent stomach cancer.
Mainstream professors and physicians received financial supports. Running 
out of money is a problem. The world top share product, which is originated by 
a Japanese firm, suppresses the immune elimination of cancer cells by NK cell 
inactivation since histamine is essential to activate NK cells.
Japanese pharmaceutical firms advertised that new PPI (Proton pump inhibitor) 
therapy did not cure the symptoms. Eradication of gastric ulcer and gastric cancer 
causative bacteria, Helicobacter pylori, by PPI was a standard therapy in Europe 
and the US. Approval in Japan delayed more than 10 years. PPI became the first 
choice once the patent for top-seller H2 blocker expired. This witnesses the strength 
of dominance.
Table 5 shows that the ratio of deaths by stomach cancer is the highest among 
other countries in 2005 (before the PPI era). The death rate of stomach cancer in 
Japan is 10 times higher than that of Americas. It is known in the pharmaceutical 
industry that this is due to the widespread of a top-seller H2 blocker in Japan.
3. Anti-cancer therapy is mainly by drug therapy in combination with surgery or 
radiation. Anticancer drugs control the growth of cancerous cells by toxicity.
When antibodies that suppress the growth factors of breast cancer cells had 
been developed, firms, professors and physicians have denied every time. As proof 
of lack of intension, they do not conduct in-hospital trials for applicants like toxic 
drug candidates. The drug delay has happened all over the world.
All professionals have denied the effectiveness of antibody drugs and the anti-
cervical cancer vaccine mentioned above. HTLV (Human T) was first discovered as 
a causative virus of adult T-cell lymphoma (ATL) by Dr. Hinuma at Kyoto University 
in 1977. A negative campaign against cancer viruses’ existence was held through the 
20th century. Many scholars, who have been associated with the prestigious profes-
sors of the mainstream, have been openly, unfounded, and emotional, and have 
continued to deny until very recently. It has been proved that more than 30 percent 
of cancers have been caused by cancer viruses, which are increasing year by year.
4. Rheumatoid arthritis destroys joints due to autoimmunity, and eventually the 
organs are gradually destroyed, resulting in multiple organ failure and death. 
MTX (methotrexate), which have an immunosuppressive effect on symptom-
atic treatment, is widely used. New antibody therapy (anti-TNF antibody), 
Cancer Death Overall Stomach Cancer Lung Cancer
Japan 303.3 52.2 67.6
Americas 207.2 5.3 65.5
UK 279.2 13.7 70.0
France 303.2 11.0 72.0
Source: Cancer Statistics, National Cancer Center Japan.
Table 5. 
The ratio of deaths by stomach cancer per 100,000 men in 2005.
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which blocked immune cells from killing patients’ bodies, were neglected, 
despite mainstreamers watched an evidence that patients with difficulty of 
walking started walking quickly after injection. If they are cured completely, 
they do not need to visit doctors.
MTX therapy is practiced as a standard treatment all over the world and satis-
fied doctors. MTX is mildly toxic but are popular as a first choice, so the conclusion 
was there was no need to change treatments.
5. EPO(Erythropoietin) stimulates red blood cell proliferation (erythropoiesis) 
in the bone marrow. EPO is an alternative to blood transfusions, but it was 
denied that red blood cell transfusion is cheap.
EPO is now used in treating anemia resulting from chronic kidney disease, 
chemotherapy induced anemia in patients with cancer, inflammatory bowel disease 
(Crohn’s disease and ulcerative colitis) and myelodysplasia caused by cancer chemo-
therapy or radiation.
The risk of viral infection is greatly reduced. If a cancer patient can be operated on 
without blood transfusion, the rate of recurrence and metastasis of cancer is greatly 
reduced because immune disturbance is not caused without blood transfusion.
6. Biopharmaceuticals are categorized 5 major classes; extracts from living 
systems, recombinant products, vaccines, gene therapy, RNA or DNA drugs 
(nucleic acid drugs).
G-CSF (Granulocyte Colony-stimulating Factor) is a type of growth factor. 
Patients might have G-CSF after chemotherapy to help their white blood cells 
recover after treatment.
It was rejected by mainstreamers except bio-venture firm, because of different 
treatment criteria. Mainstreamers and larger pharmaceutical firms resisted and 
opposed the new treatment to stimulate granulocyte proliferation.
Total market size of Biopharmaceuticals is beyond the half. This means the util-
ity of biopharmaceuticals has been neglected by mainstreamers and professionals. 
According to IQVIA World Review Analyst 2020 forecast [24], the pharmaceutical 
market in 2019 was $ 1.2624 trillion, up 3.3% from last year. The market share of 
the top 100 pharmaceutical sales items (hereinafter referred to as the top items) 
was about 32%. Total sales of top items in 2019 were $ 401.3 billion, up 6.4% from 
last year. According to the technical classification of active ingredients (chemi-
cally synthesized drugs and biopharmaceuticals), there are 55 items of chemically 
synthesized drugs and 45 items of biopharmaceuticals, which is higher than the 
2018 survey (59 items and 41 items, respectively). biopharmaceuticals increased 
by 4 items. Among the top items, 10 items have been replaced since 2018, of which 
5 items have been replaced by 9 items and biopharmaceuticals items have been 
replaced by 5 items and 1 item has been replaced year by year. In addition, biophar-
maceuticals sales accounted for $ 209.7 billion, 52% of top item sales, and although 
synthetic drugs accounted for more items, biopharmaceuticals accounted for more 
than half of sales for the first time in previous surveys.
7. Regeneration
Regenerative medicine will be the ultimate medical treatment aiming at immortal-
ization and complete cure. Drug companies and mainstreamers do not develop com-
plete cures that will eliminate the need for drug administration and shrink the market.
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Around 1988, the author applied to MHW (the Ministry of Health and Welfare), 
Japan Health Sciences Foundation, major firms and JPMA (Japan Pharmaceutical 
Manufacturers Association) a research project on the generation of pluripotent cells 
by gene transfer as an innovative research theme. The proposal was neglected to 
adopt as a research theme because complete cures eliminate the market.
All doctors have still denied that the cells were reprogrammed. This is incom-
patible with a basic principle of embryology, the developmental process of higher 
organisms repeats evolutionary process (the law of developmental repetition, 
Haeckel’s Law). For biologists, regeneration overturns their basic assumptions.
That is why mainstreamers at Kyoto University still underestimate the possibility 
of iPS cells and overstate that the risk. Since the mutation rate of cells is higher in 
liquid culture than in vivo, they should develop a culture system like in the body. 
The creation of iPS cells or pluripotent cells by direct injection of RNA into the 
human body would reduce the risk of genetic mutation.
8. Oligonucleotide therapeutics uses basically RNA or DNA. Oligonucleotides 
are nucleic acid polymers with the potential to treat or manage a wide range of 
diseases and can be used to modulate gene expression via a range of processes 
including RNAi (RNA interference), target degradation by RNase H-mediated 
cleavage, splicing modulation, non-coding RNA inhibition, gene activation 
and programmed gene editing. As such, these molecules have potential thera-
peutic applications for myriad indications, with several oligonucleotide drugs 
recently gaining approval [25]. As shown in the above Nature Review [25], 
although the majority of oligonucleotide therapeutics have focused on gene 
silencing, other strategies are being delayed or neglected by mainstreamers.
Oligonucleotide drugs such as RNA or DNA injection for producing antibodies 
was supposed to be ineffective and risky without evidence. Well-known main-
stream scholars slandered the developers. As a matter of fact, only venture compa-
nies were developing quietly.
Suddenly in early 2020, rapid vaccine development and urgent supply were 
needed to prevent the spread of coronavirus. Speed-up approval of RNA or DNA 
vaccines against coronavirus was given worldwide, but Japan was the lowest in 
the world.
As a matter of life and death, the clinical trials were urged to conduct develop-
ment of coronavirus vaccine. Similarly, immunotherapy for cancer should be as safe 
and effective as vaccines in post-infection adverse effects. However, almost profes-
sionals and drug companies are still not willing to admit.
RNA produces iPS cells therapeutics will repair complete body and will pave the 
way for spontaneous healing with their own cells. There is some evidence that such 
treatments are effective. As an example, in our brains, 50,000 nascent neural stem 
cells are born every day. Even at the age of 80, the same amount of regeneration as 
young people happens. Full-function recovery therapeutics by oligonucleotide will 
become the ultimate complete cure treatment. Complete healing of aging or dis-
eases is unacceptable to mainstreamers. They do not intend to contribute to human 
healthcare, because they will definitely lose the hegemony in the current system. 
How to solve the problem is the next issue to be discussed.
4.4  Freedom from the centrality of hegemony by setting network neutrality 
through commons of information
Through the discussions so far, author has analyzed the actions taken by main-
stream people in medical care and healthcare, which deal with life and health. The 
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mainstreamers always win any new product developments that directly competes 
with and therefore replace the mainstream [19–22].
In case of indirect competition, mainstreamers inevitably lose any new product 
developments. As far as a new does not directly compete with the mainstream, 
they deny the fact until the mainstream is replaced. Even if treatments begin to be 
adopted, mainstreamers always deny and criticize the use of alternative treatments. 
For example, the evidence is that the discovery of the presence of a cancer virus, the 
ability to artificially generate pluripotent stem cells, and the fact that RNA can be 
used for treatment are not acknowledged and criticized.
Mainstreamers do not approve such facts until they understand that they will be 
replaced soon. Due to the dominant structure of the mainstream, novel therapeu-
tics such as desensitization therapy using oral immunity for pollinosis and cervical 
cancer virus vaccination for men many innovative approaches delayed approvals by 
the Authorities. Many have been sacrificed by mainstreamers.
The method to eliminate such evils and realize truly useful health care is 
required. The effect and influence of the commons of information will become 
a solution to eliminating adverse events caused by the hegemonic mainstream. 
As the most effective means in the coming digital healthcare era, commons of 
information is now under construction. In July of 2020, Japanese Ministry of 
Health, Labor and Welfare confirmed its policy of intensively working over the 
next two years to operate a system that allows medical institutions and pharma-
cies nationwide to share medical information of patients online and use it for 
patient treatment and health promotion. Customers and service providers such 
as doctors pharmacists, health instructors, nurses in charge can check the treat-
ment history. In these ways, the information that the doctor has kept secret is 
inevitably made public and reviewed, which can lead to criticism in some cases. 
Even if that patient can find a provider, the existing health care system is likely to 
create a lot of unnecessary impediment and expense in the US. Digital pharmacy 
expands access to professional healthcare. It would be a great start to access and 
utilize such kind of commons of information.
With the rapid penetration of the mobile Internet into everyday life, the ruler of 
the information is changing. Innovative ideas are realized instantly on the mobile 
and advanced media, according to instant innovation [26–28].
As various media are put to practical use in general life, the media affects not 
only on everything in our society and life. As a result of the widespread use of 
mobile terminals, advanced media has being breaking down the barriers built by 
the mainstream with hegemony by setting net neutrality in the instant communica-
tion through mobile.
Mobiles process various information in parallel and multiple parallel worlds 
exist at the same time. Information selection has made it possible for users to create 
necessary information from the side that creates information, and users have come 
to directly experiment and implement it. This kind of instant communication leads 
instant innovation [26].
Already, some app platforms for disclosure and use of medical information have 
been developed. Open information will be searchable in Information Commons, a 
platform for sharing information. There is no doubt that patients and end users who 
need information will become aware of everything from daily health care to disease 
information.
Instant innovation that happens on mobile is the opposite of traditional inno-
vation, because end users choose their best. Moreover, the product is evaluated 
immediately. Therefore, the adjustment is performed so that it is easy to use from 
the customer side. A platform that is open and can bring the best solution survives 
automatically [26].
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The effect and influence of the commons of information eliminate adverse 
events caused by the hegemonic mainstream. As the most effective means in the 
coming digital healthcare era, the commons of information has instantly created 
network neutrality on the mobiles. The network neutrality is independent of the 
mainstream. Therefore, only the commons of information, which is a platform with 
the following three points, survive:
1. Allow commons of information to enable fair use and fair search of in-
formation.
2. The commons of information release the cognitive bias set by mainstream.
3. The platform with fair use develop fairness of digital management and digital 
economics in the healthcare.
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